A Phase II/III Study of Peri-Operative Nivolumab (nivo) and Ipilimumab (ipi) in Patients (pts) with Locoregional Esophageal (E) and Gastroesophageal Junction (GEJ) Adenocarcinoma: Results of the Neoadjuvant Pathologic Complete Response (pcr) Rate (ECOG-ACRIN EA2174).
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined